CRTC3 Antibody [M6H14] Datasheet

Biological Description

Specificity	CRTC3 Antibody [M6H14] detects endogenous levels of total CRTC3 protein.
Background	CRTC3 (CREB‑regulated transcription coactivator 3) is a member of the CRTC family of CREB coactivators that links cAMP and Ca²⁺/stress signaling to transcriptional control of energy metabolism, catecholamine responsiveness, and inflammatory outputs, acting in a phosphorylation‑regulated, Ser133‑independent manner to potentiate CREB1 on both consensus and variant cAMP response elements. The protein contains an N‑terminal CREB‑binding domain with TORC‑conserved regions that dock onto the bZIP region of CREB1 and enhance its interaction with the TFIID subunit TAF4, and a C‑terminal serine‑rich transactivation domain that is heavily phosphorylated by salt‑inducible kinases (SIKs) and other kinases; phosphorylation promotes 14‑3‑3 binding and cytoplasmic retention, whereas dephosphorylation, often via PP2A‑B55 holoenzymes or phosphatases activated downstream of cAMP, calcium, or mitogens, releases CRTC3 to accumulate in the nucleus and coactivate CREB target genes. In adipocytes, CRTC3 is activated by catecholamine signaling through β‑adrenergic receptors in a manner that paradoxically dampens cAMP production: nuclear CRTC3 upregulates the regulator of G‑protein signaling RGS2, which terminates Gs signaling at the β‑adrenergic receptor level and attenuates adenylate cyclase activity, leading to reduced protein kinase A activation, blunted lipolysis, and suppression of thermogenic programs; this negative feedback positions CRTC3 as a transcriptional brake on catecholamine‑driven energy expenditure that promotes positive energy balance and susceptibility to obesity and insulin resistance. Human genetic analyses identify a gain‑of‑function CRTC3 variant associated with increased adiposity, and adipose‑tissue CRTC3 activity increases with high‑fat feeding and obesity, linking this coactivator to metabolic syndrome and making it a potential therapeutic target for enhancing brown and beige fat thermogenesis and improving systemic glucose homeostasis. Beyond adipocytes, CRTC3 acts as a selective coactivator for a subset of CREB‑dependent genes in multiple tissues: it cooperates with PPARGC1A to induce mitochondrial biogenesis in muscle cells, regulates steroidogenic genes such as StAR in endocrine contexts, and functions as a coactivator for HTLV‑1 Tax‑dependent transcription of viral long terminal repeats, integrating hormonal, metabolic, and viral signals at CREB‑controlled promoters and enhancers. In the immune system, phosphorylation of CRTC3 by SIKs in macrophages controls the interconversion between classically activated and regulatory phenotypes, with dephosphorylated CRTC3 entering the nucleus to enhance CREB‑driven IL‑10 production and modulate inflammatory tone, defining a SIK–CRTC3 axis that couples metabolic and stress cues to cytokine programming.

Specificity

CRTC3 Antibody [M6H14] detects endogenous levels of total CRTC3 protein.

Background

CRTC3 (CREB‑regulated transcription coactivator 3) is a member of the CRTC family of CREB coactivators that links cAMP and Ca²⁺/stress signaling to transcriptional control of energy metabolism, catecholamine responsiveness, and inflammatory outputs, acting in a phosphorylation‑regulated, Ser133‑independent manner to potentiate CREB1 on both consensus and variant cAMP response elements. The protein contains an N‑terminal CREB‑binding domain with TORC‑conserved regions that dock onto the bZIP region of CREB1 and enhance its interaction with the TFIID subunit TAF4, and a C‑terminal serine‑rich transactivation domain that is heavily phosphorylated by salt‑inducible kinases (SIKs) and other kinases; phosphorylation promotes 14‑3‑3 binding and cytoplasmic retention, whereas dephosphorylation, often via PP2A‑B55 holoenzymes or phosphatases activated downstream of cAMP, calcium, or mitogens, releases CRTC3 to accumulate in the nucleus and coactivate CREB target genes. In adipocytes, CRTC3 is activated by catecholamine signaling through β‑adrenergic receptors in a manner that paradoxically dampens cAMP production: nuclear CRTC3 upregulates the regulator of G‑protein signaling RGS2, which terminates Gs signaling at the β‑adrenergic receptor level and attenuates adenylate cyclase activity, leading to reduced protein kinase A activation, blunted lipolysis, and suppression of thermogenic programs; this negative feedback positions CRTC3 as a transcriptional brake on catecholamine‑driven energy expenditure that promotes positive energy balance and susceptibility to obesity and insulin resistance. Human genetic analyses identify a gain‑of‑function CRTC3 variant associated with increased adiposity, and adipose‑tissue CRTC3 activity increases with high‑fat feeding and obesity, linking this coactivator to metabolic syndrome and making it a potential therapeutic target for enhancing brown and beige fat thermogenesis and improving systemic glucose homeostasis. Beyond adipocytes, CRTC3 acts as a selective coactivator for a subset of CREB‑dependent genes in multiple tissues: it cooperates with PPARGC1A to induce mitochondrial biogenesis in muscle cells, regulates steroidogenic genes such as StAR in endocrine contexts, and functions as a coactivator for HTLV‑1 Tax‑dependent transcription of viral long terminal repeats, integrating hormonal, metabolic, and viral signals at CREB‑controlled promoters and enhancers. In the immune system, phosphorylation of CRTC3 by SIKs in macrophages controls the interconversion between classically activated and regulatory phenotypes, with dephosphorylated CRTC3 entering the nucleus to enhance CREB‑driven IL‑10 production and modulate inflammatory tone, defining a SIK–CRTC3 axis that couples metabolic and stress cues to cytokine programming.

Usage Information

Application

WB

Dilution

WB

1:1000

Reactivity

Human, Mouse, Rat, Monkey

Source

Rabbit Monoclonal Antibody

MW

70 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/21164481/
https://pubmed.ncbi.nlm.nih.gov/30611118/

Application Data

WB

Validated by Selleck

Lane 1: MCF7, Lane 2: Hela, Lane 3: Jurkat